Janssen/Shire Reminyl
Executive Summary
"Hopefully we will be receiving the final [Reminyl] approval in a reasonable time frame," J&J CEO Ralph Larsen tells Jan. 23 analysts meeting. "We are prepared and have taken steps to introduce this important product into the U.S. very rapidly." The Alzheimer's agent galantamine has been "approvable" at FDA since July 31 (1"The Pink Sheet" Aug. 7, 2000, In Brief)